Investors Buy Shares of Exelixis, Inc. (EXEL) on Weakness
Traders bought shares of Exelixis, Inc. (NASDAQ:EXEL) on weakness during trading on Wednesday. $34.83 million flowed into the stock on the tick-up and $18.33 million flowed out of the stock on the tick-down, for a money net flow of $16.50 million into the stock. Of all stocks tracked, Exelixis had the 25th highest net in-flow for the day. Exelixis traded down ($0.56) for the day and closed at $24.23
A number of brokerages have weighed in on EXEL. TheStreet raised Exelixis from a “c” rating to a “b-” rating in a research report on Monday, August 7th. William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Thursday, July 27th. Cowen and Company reissued an “outperform” rating on shares of Exelixis in a research report on Thursday, August 10th. Needham & Company LLC boosted their price target on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Finally, BidaskClub downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $31.38.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.21. The firm had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The company’s revenue for the quarter was up 145.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) EPS.
In other Exelixis news, insider Gisela Schwab sold 100,000 shares of the stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $23.79, for a total value of $2,379,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Morrissey sold 300,000 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $26.90, for a total transaction of $8,070,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 970,152 shares of company stock valued at $25,923,457. Company insiders own 5.10% of the company’s stock.
Large investors have recently bought and sold shares of the business. First Quadrant L P CA purchased a new stake in Exelixis in the 2nd quarter valued at about $144,000. Fisher Asset Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $213,000. Wetherby Asset Management Inc. purchased a new stake in shares of Exelixis during the 2nd quarter worth approximately $218,000. Caxton Associates LP purchased a new stake in shares of Exelixis during the 2nd quarter worth approximately $227,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Exelixis during the 2nd quarter worth approximately $247,000. Hedge funds and other institutional investors own 78.71% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2017/11/01/investors-buy-shares-of-exelixis-inc-exel-on-weakness.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.